GlassScriptPhysician profile
Jascha C Rubin
NPI 1932342185
$13,100.19
in general payments reported to CMS, 2019-2025
84 companies · $4,384 in 2025
The $4,384 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,724 · 2020: $495 · 2021: $395 · 2022: $389 · 2023: $1,624 · 2024: $3,089 · 2025: $4,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,928 · Education: $644 · Consulting Fee: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,928.03 |
| Education | $643.95 |
| Consulting Fee | $525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,586.51 | 2019-2025 | Calquence, Enhertu, Tagrisso |
| Janssen Biotech, INC. | $904.59 | 2019-2025 | Darzalex, Erleada, Talvey |
| E.R. Squibb & Sons, L.L.C. | $684.03 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Novartis Pharmaceuticals Corporation | $618.25 | 2019-2025 | |
| Astellas Pharma US INC | $499.07 | 2019-2025 | Xospata, Vyloy, Xtandi |
| Daiichi Sankyo INC. | $433.54 | 2019-2025 | Enhertu, Datroway |
| Pfizer INC. | $402.46 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $386.22 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $371.34 | 2019-2025 | Jakafi, Monjuvi, Niktimvo |
| Genzyme Corporation | $363.81 | 2019-2025 | |
| Glaxosmithkline, LLC. | $330.90 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Genentech USA, INC. | $325.92 | 2019-2025 | Venclexta, Polivy, Tecentriq |
| Abbvie INC. | $307.60 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $284.07 | 2024-2025 | Ultomiris, Soliris |
| Sobi, INC | $251.93 | 2024-2025 |
Show all 84 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jascha Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.